Business
Todos Medical Enters Into Exclusive Distribution Agreement With NLC Pharma for Saliva-based Onsite COVID-19 Diagnostic Test
Todos Medical Enters Into Exclusive Distribution Agreement With NLC Pharma for Saliva-based Onsite COVID-19 Diagnostic Test.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n  NLC Pharma has patented and developed 3C protease platform for SARS and other viruses  3C protease measures viral replication, as a rapid detection method for COVID    Todos to develop At-Home Saliva test kit w/ digital analysis & software REHOVOT, Israel, and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an exclusive worldwide distribution agreement with Israel-based NLC Pharma to commercially develop its patented virus-focused 3C Protease diagnostic platform for the diagnosis of COVID-19.  “3C Protease quantitation presents a unique approach to viral replication monitoring, and could prove to be a significant tool in the fight against COVID-19,” said Jorge Leon, PhD, Senior Medical Advisor to Todos. The 3C Protease is a novel target for COVID-19 drug development. It has properties that make it a strong saliva-based biomarker candidate for viral load measurement because it binds to full length viral RNA and is required prior to coronaviruses exiting host cells before going to infect other cells, and it secretes into the saliva for measurement of viral load. Because only full-length RNA is detected, it overcomes potential limitations of technologies that detect viral fractions, such as antigen testing and certain polymerase chain reaction (PCR)-based tests that often yield false positives post-infection. Todos intends to develop an At-Home (or Onsite) COVID-19 diagnostic 3C Protease-based test kit for use as a diagnostic for COVID-19, using existing cell phone camera technology and proprietary software to complete the data analysis. The companies will work together towards filing an Emergency Use Authorization (EUA) application with the FDA in the United States and the Ministry of Health in Israel. NLC previously developed working prototypes from its 3C Protease platform for rapid detection of HRV (common cold), HMV (viral meningitis), and SARS.   “As we build Todos into a niche provider of COVID-19 testing solutions to...